Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D MedicinesHKSE:01244 +3.33%49 Days Payable is 1,080.91 as of Dec. 2025, which is 230% above its 10-year median of 327.56. GuruFocus rates HKSE:01244 with a GF Score™ of 49/100 and a GF Value™ of HK$3.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, 3D Medicines ranks better than 85.63% on this metric.
The historical data trend for 3D Medicines's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01244 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, 3D Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Medicines Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where 3D Medicines's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
3D Medicines's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Medicines (HKSE:01244) has a Days Payable of 1,080.91 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3D Medicines and its competitors. This is 230% above median its historical median of 327.56. Over the past decade, 3D Medicines' Days Payable has ranged from 86.39 to 897.63. According to the industry distribution chart, 3D Medicines ranks #101 out of 703 companies in the Biotechnology industry, placing it in the top 14.4%.
Is 3D Medicines' Days Payable too high?
3D Medicines' current Days Payable of 1,080.91 is 230% above median its 10-year median of 327.56. Over the past 10 years, this metric has ranged from a low of 86.39 to a high of 897.63. The Biotechnology industry median Days Payable is 112.39. 3D Medicines' value of 1,080.91 is 861.7% above this industry median. Based on the distribution chart, 3D Medicines ranks #101 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Medicines ranks #101 out of 703 companies for Days Payable. This places 3D Medicines in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.39. 3D Medicines' value of 1,080.91 is 861.7% above this benchmark. Historically, 3D Medicines' own Days Payable has ranged from 86.39 to 897.63 over the past decade. While the company's 10-year median is 327.56 vs. the industry median of 112.39, 3D Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Medicines's current Days Payable of 1,080.91 is 861.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3D Medicines and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Medicines's current Days Payable is 1,080.91, which is 230% above median its own 10-year median of 327.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current Days Payable is 1,080.91, which is 230% above median its 10-year median of 327.56 and 861.7% above the Biotechnology industry median of 112.39. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Days Payable is 1,080.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Medicines (HKSE:01244) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued.
The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15.
GuruFocus considers 3D Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01244:
Days Payable: 1,080.91 (230% above median its 10-year median of 327.56)
GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
Industry Position: 861.7% above the Biotechnology median (#101 of 703)
No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score
Get the complete analysis for HKSE:01244
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01244 has been successfully added to your 
